Download Free Strategic Accumulation Of Patents In The Pharmaceutical Industry And Patent Thickets In Complex Technologies Two Different Concepts Sharing Similar Features Book in PDF and EPUB Free Download. You can read online Strategic Accumulation Of Patents In The Pharmaceutical Industry And Patent Thickets In Complex Technologies Two Different Concepts Sharing Similar Features and write the review.

This book traces the academic footprint of Hanns Ullrich. Thirty contributions revolve around five central topics of his oeuvre: the European legal order, competition law, intellectual property, the regulation of new technologies, and the global market order. Acknowledging him as a trailblazer, the book aims to capture how deeply Hanns Ullrich has influenced contemporaries and subsequent generations of scholars. The contributors re-iterate the path-breaking patterns of his teachings, such as his contemplation of intellectual property as embedded in competition, the necessity of balancing private and public interests in intellectual property law, the policies of market integration, and the peculiar relationship of technological advancement and protectionism.
The history of patent harmonization is a story of dynamic actors, whose interactions with established structures shaped the patent regime. From the inception of the trade regime to include intellectual property (IP) rights to the present, this book documents the role of different sets of actors – states, transnational business corporations, or civil society groups – and their influence on the structures – such as national and international agreements, organizations, and private entities – that have caused changes to healthcare and access to medication. Presenting the debates over patents, trade, and the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement), as it galvanized non-state and nonbusiness actors, the book highlights how an alternative framing and understanding of pharmaceutical patent rights emerged: as a public issue, instead of a trade or IP issue. The book thus offers an important analysis of the legal and political dynamics through which the contest for access to lifesaving medication has been, and will continue to be, fought. In addition to academics working in the areas of international law, development, and public health, this book will also be of interest to policy makers, state actors, and others with relevant concerns working in nongovernmental and international organizations.
This book focuses on the economic aspects of intellectual property (IP). It includes considerations of the wider category of intangible assets. However, the primary focus is devoted to patents which the author argues are the most vivid example of the Tragedy of Intangible Abundance (TIA). TIA touches upon a key issue in the contemporary economy. On the one hand, there is an enormous supply of IP, yet, on the other hand, such an abundance does not necessarily solve existing issues but rather creates new ones as well. This book elaborates on the reasons for the emergence of TIA and its consequences. The author uses clear metaphors to explain very complex issues. The book provides a valuable and interdisciplinary analysis of the field and offers practical solutions. It is based on the data collected by the author during the qualitative research he conducted among a group of start-ups. It presents guidance on determining which instrument is the most efficient for a particular situation. It also provides arguments for decision-makers and their advisors as to why a more open approach towards intellectual property would be more beneficial under many circumstances in the contemporary economy. While universal issues are addressed, the author distinguishes the European perspective too. The book is written in a clear and concise style and covers all of the crucial aspects of IP management. It will find an audience among scholars of economics and business.
This book is a history of medicines and the commercial actors that make and sell them, covering the 140 years since the modern pharmaceutical industry came into being. It is written in a lively and accessible way, aiming at a general audience that combines historical narrative with fascinating case studies on drug discovery and commercialization, from the rat poison that became warfarin, to a cardiovascular treatment that was turned into Viagra. In a non-partisan way it also examines some of the less noble manifestations of corporate behavior, concluding with an agenda for reform.It is hard to think of anything nobler than to bring to the world a medicine that saves lives. And over 140 years of history, the pharmaceutical industry has produced a range of remarkable products, albeit typically with external scientific and financial support. Making medicines is a very big and profit-driven business, and the industry does not always make the right products for the right people, or at the right prices.The industry wields immense power over lives and economies. How has it risen to this position of dominance? Are the interests of the industry and the public in balance? What should we admire about the industry? What should we criticise and seek to change? The importance of this book lies in the fact that we are all stakeholders in this industry whether or not we own shares, so we all need answers to these questions.Related Link(s)
The Routledge Companion to Gender and COVID-19 is the first comprehensive research guide for researchers and students who seek to study and evaluate the complex relationship between gender and COVID-19. This interdisciplinary collection touches on two major themes: first, how gender played a central role in shaping access to testing, treatment, and vaccines. Second, how the pandemic not only deepened existing gender inequalities, but also those along the lines of race, class, sexuality, disability, and immigration status. Bringing together a diverse range of international scholars across a number of disciplinary perspectives, this intersectional and comparative focus on COVID explores topics including the pandemic’s impact on families, employment, childcare and elder care, human rights, as well as gender and political economy and leadership, public health law, disability rights, and abortion access. The Routledge Companion to Gender and COVID-19 is an essential volume for scholars and students of Law, Gender Studies, Sociology, Health, Economics, and Politics.
This study has emerged from an ongoing program of trilateral cooperation between WHO, WTO and WIPO. It responds to an increasing demand, particularly in developing countries, for strengthened capacity for informed policy-making in areas of intersection between health, trade and IP, focusing on access to and innovation of medicines and other medical technologies.
This report examines the importance of intellectual property (IP), ranging from patents, copyright, design and trade marks, and whether in the age of globalization, digitization and increasing economic specialization it still creates incentives for innovation, without unduly limiting access to consumers and stifling further innovation. The report does recommend a radical overhaul of the system, with the review concentrating on three areas, and setting out the following recommendations: (i) strengthening enforcement of IP rights, whether through clamping down on piracy or trade in counterfeit goods; (ii) reducing costs of registering and litigating IP rights for businesses large and small; (iii) improving the balance and flexibility of IP rights to allow individuals, businesses and institutions to use content in ways consistent with the digital age.
WIPO's latest World Intellectual Property Report (WIPR) explores the role of IP at the nexus of innovation and economic growth, focusing on the impact of breakthrough innovations.
The big stories -- The skills of the new machines : technology races ahead -- Moore's law and the second half of the chessboard -- The digitization of just about everything -- Innovation : declining or recombining? -- Artificial and human intelligence in the second machine age -- Computing bounty -- Beyond GDP -- The spread -- The biggest winners : stars and superstars -- Implications of the bounty and the spread -- Learning to race with machines : recommendations for individuals -- Policy recommendations -- Long-term recommendations -- Technology and the future (which is very different from "technology is the future").